329P ORCHARD: Osimertinib + necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinib
Jonathan W. Riess(University of California Davis Medical Center), H.A. Yu(Memorial Sloan Kettering Cancer Center), J.W. Goldman(University of California, Los Angeles), N. Hewson(AstraZeneca (United Kingdom)), Brayan Merchan Ruiz(AstraZeneca (Netherlands)), Z. Piotrowska(Massachusetts General Hospital), I. Okamoto(Kyushu University), S. Ponce Aix(Spanish National Cancer Research Centre), J. Cosaert(AstraZeneca (United Kingdom)), J. Maidment(AstraZeneca (United Kingdom)), J.A. De Langen(The Netherlands Cancer Institute), S. Teraoka(Wakayama Medical University), S.B. Goldberg(Yale University), H. Ambrose(AstraZeneca (United Kingdom)), K.H. Tang(AstraZeneca (United States))
Cited by 4
Related Papers
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|805
siRNA-directed inhibition of HIV-1 infection
|Nature Medicine|2002|777
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|670